Evaluating and treating small cell lung cancer

SCLC accounts for less than 15% of newly diagnosed lung cancers and can be distinguished from NSCLC by a high cell turnover rate and a rapidly progressive disease course, with a median survival of 3 months without treatment in extensive disease

by Dr Alexandra Leary and Dr Mary O'Brien
Coloured X-ray of the chest of a patient with SCLC (Photograph: PR M Brauner/SPL)
Coloured X-ray of the chest of a patient with SCLC (Photograph: PR M Brauner/SPL)

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package